Jump to content
Forum All Steroids

Etudes sur l'albuterol (salbutamol)

Robocop

By Robocop,
in Autres

 Share

Recommended Posts

Robocop KING FORUM

Robocop

Posted
Posted

Suite à une discussion avec un membre qui me les avaient demandé je fais un topic avec les études faites sur l'albutérol pour les non bilingue des études sur des patients atteint de dystrophie musculaire on reçu des doses d'albuterol les résultats ont été une augmentation de la masse sèche et une diminution de la masse grasse.

 

Hésitez à postez celle dont vous avez trouvé également

 

 

étude n°1

 

Neurology. 2008 Jan 8;70(2):137-43. Epub 2007 Oct 17.Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy.Skura CL, Fowler EG, Wetzel GT, Graves M, Spencer MJ.David Geffen School of Medicine at UCLA, 635 Charles Young Drive South, NRB1 Room 401, Los Angeles, CA 90095-7334, USA.BACKGROUND: Albuterol is a beta-2 agonist that has been demonstrated to increase muscle strength in studies in animals and humans. Based on a pilot study of extended-release albuterol Repetabs in children with dystrophinopathies, the authors conducted a randomized, double-blind, placebo-controlled study with a crossover design. METHODS: Fourteen boys with Duchenne or Becker muscular dystrophy, 6 to 11 years old, completed two treatment periods (albuterol and placebo), 12 weeks each, separated by a 12-week washout period. As the albuterol Repetab formulation was no longer available, an alternate extended release albuterol was used (Volmax, 12 mg per day). Outcome measurements included 1) lean body mass, 2) fat mass, 3) isometric knee extensor and flexor moments, 4) manual muscle testing, and 5) timed functional tests. RESULTS: Lean body mass was significantly higher for subjects following albuterol treatment compared to placebo treatment, while fat mass was significantly lower. No differences were found in isometric knee moments or manual muscle tests. Time to run/walk 30 feet was improved following albuterol. CONCLUSIONS: Short-term treatment with extended release albuterol may increase lean body mass, decrease fat mass, and improve functional measures in patients with dystrophinopathies. However, the significant change in strength of specific muscle groups found in the pilot study was not observed in the present study. These findings may be attributed to differences in the drug release and kinetics between Repetab and Volmax formulations as they affect the concentration of available beta-2 receptors on the muscle cell surface differently. 

 

 

 

 

étude n°2 : 

 

Background/Objectives: Animal and human studies suggest that β2-adrenergic agonists exert anabolic effects on muscles, inducing and preventing atrophy after a variety of insults. Based on data from an open-label trial of albuterol in 15 patients with facioscapulohumeral dystrophy (FSHD), the authors conducted a randomized, double-blind, placebo-controlled trial of sustained-release albuterol in this disease.Methods: Ninety patients were randomized to three groups: placebo; 8.0 mg albuterol twice daily; or 16.0 mg albuterol twice daily. Patients were treated for 1 year with assessments at baseline and weeks 13, 26, and 52. The primary outcome was the 52-week change in global strength by maximum voluntary isometric contraction testing (MVICT). Secondary outcomes included changes at 52 weeks in strength by manual muscle testing (MMT), grip strength, functional testing, and muscle mass assessed by dual energy x-ray absorptiometry (DEXA).Results: Eighty-four patients completed the study. The mean changes in composite MVICT scores were not significantly different between the groups (mean ± SD: placebo 0.20 ± 0.91; low dose −0.04 ± 0.84; high dose 0.08 ± 0.98). Similarly, there were no differences in the mean MMT change (placebo 0.04 ± 0.16; low dose −0.03 ± 0.13; high dose 0.00 ± 0.15). Grip improved in both treatment groups compared to placebo (placebo −0.53 ± 4.13, low dose +1.90 ± 3.34 [p = 0.02], high dose +1.70 ± 4.13 [p = 0.03]). The high-dose group had a significant increase in lean mass by DEXA (+1.57 ± 1.71 kg) compared to placebo (0.25 ± 2.24; p = 0.007). Albuterol was well tolerated; side effects included cramps, tremors, insomnia, and nervousness.Conclusions: Although albuterol did not improve global strength or function in patients with FSHD, it did increase muscle mass and improve some measures of strength. 

Link to comment
Share on other sites
bullrot1700 All-Steroidien

bullrot1700

Posted
Posted

L albuterol c est quasiment similaires au clembuterol, non?

Car quand j ai entendu parler du clembuterol au début il disait que sa faisait prendre de la masse sèche tout en baissant la masse graisseuse

et maintenant on dit quand même que sa baisse la masse graisseuse mais que sa ne fait pas prendre de masse sèche, pire que sa, que sa cataboliserai donc qu il faudrait être sous testo pour ne pas fondre le muscle

Link to comment
Share on other sites
bullrot1700 All-Steroidien

bullrot1700

Posted
Posted

Je ne suis pas assez câler pour savoir mais j ai lu tellement de chose qui ce contredise que je je sais plus quoi en penser.

Tu entends certains dire que clembu sans testo tu vas fondre le muscle

Et d autre comme à l époque de zyzz qui disait prendre de la masse sèche tout en perdant le gras juste avec sa. Bon, mauvais exemple quand tu lis ce qu il s envoyait à côté.

J aimerai beaucoup savoir le vrai du faux

Link to comment
Share on other sites
VeuveBlack KING FORUM

VeuveBlack

Posted
Posted

Honnêtement je n'ai pas d'études et je ne me base que sur mon expérience personnelle mais je crois sincèrement que le clen a une bonne action anti catabolique. Quand je vois l'évolution sans toucher à la diète juste avec l'ajout du clen je suis satisfait, BF de mieux en mieux (rien de grandiose mais en même temps je ne fais rien de fou pour mon BF) et masse musculaire préservée même en PCT.

Link to comment
Share on other sites
 Share
Go to topic listing
×
×
  • Create New...